{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:30:35Z","timestamp":1787056235553,"version":"build-2736575974"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T00:00:00Z","timestamp":1780012800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Singapore National Medical Research Council \u2013 Ministry of Health Industry Alignment Fund Category 2 Grant","award":["NMRC\/MOHIAFCAT2\/006\/2016"],"award-info":[{"award-number":["NMRC\/MOHIAFCAT2\/006\/2016"]}]},{"name":"Daiichi Sankyo Co. Ltd."},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23zf0127003h and JP23gm1410013h"],"award-info":[{"award-number":["JP23zf0127003h and JP23gm1410013h"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1007\/s10637-026-01621-3","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:50:55Z","timestamp":1780044655000},"page":"317-327","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Preclinical evaluation and mechanistic analysis of antitumor effects of the novel anti-CD147 antibody DS-1471a in liver cancer models"],"prefix":"10.1007","volume":"44","author":[{"given":"Hiroshi","family":"Yuita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadanori","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Tsukada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshikazu","family":"Johmura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sae","family":"Aratani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryuichi","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari","family":"Hashimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideo","family":"Yukinaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huynh The","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nakanishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Fukuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,29]]},"reference":[{"key":"1621_CR1","first-page":"1","volume":"68","author":"M Heron","year":"2019","unstructured":"Heron M (2019) Deaths: leading causes for 2017. Natl Vital Stat Rep 68:1\u201377","journal-title":"Natl Vital Stat Rep"},{"key":"1621_CR2","first-page":"7","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE et al (2022) Cancer statistics. CA Cancer J Clin 72:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"1621_CR3","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS et al (2020) Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med 382:1894\u20131905","journal-title":"N Engl J Med"},{"key":"1621_CR4","doi-asserted-by":"publisher","unstructured":"Zhang H, Zhang W, Jiang L, Chen Y (2021) Recent advances in systemic therapy for hepatocellular carcinoma. Biomark Res 10 3. https:\/\/doi.org\/10.1186\/s40364-021-00350-4","DOI":"10.1186\/s40364-021-00350-4"},{"key":"1621_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.bbrc.2020.05.005","volume":"528","author":"Y Zhou","year":"2020","unstructured":"Zhou Y et al (2020) CD147 promotes DNA damage response and gemcitabine resistance via targeting ATM\/ATR\/p53 and affects prognosis in pancreatic cancer. Biochem Biophys Res Commun 528:62\u201370","journal-title":"Biochem Biophys Res Commun"},{"key":"1621_CR6","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1097\/01.cej.0000236245.40619.c3","volume":"16","author":"Q Zhang","year":"2007","unstructured":"Zhang Q et al (2007) Expression of CD147 as a significantly unfavorable prognostic factor in hepatocellular carcinoma. Eur J Cancer Prev 16:196\u2013202","journal-title":"Eur J Cancer Prev"},{"key":"1621_CR7","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1093\/jb\/mvv127","volume":"159","author":"T Muramatsu","year":"2016","unstructured":"Muramatsu T (2016) Basigin (CD147), a multifunctional transmembrane glycoprotein with various binding partners. J Biochem 159:481\u2013490","journal-title":"J Biochem"},{"key":"1621_CR8","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s00428-024-03939-w","volume":"487","author":"Y Shigematsu","year":"2025","unstructured":"Shigematsu Y, Kanda H, Takahashi Y, Takeuchi K, Inamura K (2025) Relationships between tumor CD147 expression, tumor-infiltrating lymphocytes, and oncostatin M in hepatocellular carcinoma. Virchows Arch 487:117\u2013125","journal-title":"Virchows Arch"},{"key":"1621_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/biom11121850","volume":"11","author":"M Hassn Mesrati","year":"2021","unstructured":"Hassn Mesrati M, Syafruddin SE, Mohtar MA, Syahir A (2021) CD44: a multifunctional mediator of cancer progression. Biomolecules 11:1850","journal-title":"Biomolecules"},{"key":"1621_CR10","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","volume":"18","author":"H Hamidi","year":"2018","unstructured":"Hamidi H, Ivaska J (2018) Every step of the way: integrins in cancer progression and metastasis. Nat Rev Cancer 18:533\u2013548. https:\/\/doi.org\/10.1038\/s41568-018-0038-z","journal-title":"Nat Rev Cancer"},{"key":"1621_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.yexmp.2007.08.014","volume":"83","author":"KT Iacono","year":"2007","unstructured":"Iacono KT, Brown AL, Greene MI, Saouaf SJ (2007) CD147 immunoglobulin superfamily receptor function and role in pathology. Exp Mol Pathol 83:283\u2013295","journal-title":"Exp Mol Pathol"},{"key":"1621_CR12","first-page":"6724","volume":"8","author":"X-P Li","year":"2015","unstructured":"Li X-P, Zhang X-W, Zheng L-Z, Guo W-J (2015) Expression of CD44 in pancreatic cancer and its significance. Int J Clin Exp Pathol 8:6724\u20136731","journal-title":"Int J Clin Exp Pathol"},{"key":"1621_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.3389\/fonc.2020.00036","volume":"10","author":"Q Du","year":"2020","unstructured":"Du Q et al (2020) High expression of integrin \u03b13 predicts poor prognosis and promotes tumor metastasis and angiogenesis by activating the c-Src\/extracellular signal-regulated protein kinase\/focal adhesion kinase signaling pathway in cervical cancer. Front Oncol 10:36","journal-title":"Front Oncol"},{"key":"1621_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.yexcr.2019.03.022","volume":"379","author":"Y Wu","year":"2019","unstructured":"Wu Y et al (2019) ITGA6 and RPSA synergistically promote pancreatic cancer invasion and metastasis via PI3K and MAPK signaling pathways. Exp Cell Res 379:30\u201347","journal-title":"Exp Cell Res"},{"key":"1621_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1083\/jcb.201208172","volume":"201","author":"L Maldonado-B\u00e1ez","year":"2013","unstructured":"Maldonado-B\u00e1ez L, Cole NB, Kr\u00e4mer H, Donaldson JG (2013) Microtubule-dependent endosomal sorting of clathrin-independent cargo by Hook1. J Cell Biol 201:233\u2013247","journal-title":"J Cell Biol"},{"key":"1621_CR16","doi-asserted-by":"publisher","first-page":"2759","DOI":"10.1016\/j.yexcr.2013.08.008","volume":"319","author":"L Maldonado-Baez","year":"2013","unstructured":"Maldonado-Baez L, Williamson C, Donaldson JG (2013) Clathrin-independent endocytosis: a cargo-centric view. Exp Cell Res 319:2759\u20132769","journal-title":"Exp Cell Res"},{"key":"1621_CR17","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-020-00303-0","volume":"6","author":"J Cheng","year":"2020","unstructured":"Cheng J et al (2020) Emerging role of FBXO22 in carcinogenesis. Cell Death Discov 6:66. https:\/\/doi.org\/10.1038\/s41420-020-00303-0","journal-title":"Cell Death Discov"},{"key":"1621_CR18","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/3552793","author":"K Fukuchi","year":"2022","unstructured":"Fukuchi K et al (2022) Novel antibody exerts antitumor effect through downregulation of CD147 and activation of multiple stress signals. J Oncol. https:\/\/doi.org\/10.1155\/2022\/3552793","journal-title":"J Oncol"},{"key":"1621_CR19","doi-asserted-by":"publisher","first-page":"5160","DOI":"10.1158\/1078-0432.CCR-12-2408","volume":"18","author":"S Kopetz","year":"2012","unstructured":"Kopetz S, Lemos R, Powis G (2012) The promise of patient-derived xenografts: the best laid plans of mice and men. Clin Cancer Res 18:5160\u20135162","journal-title":"Clin Cancer Res"},{"issue":"13","key":"1621_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23136894","volume":"23","author":"L Chuli\u00e1-Peris","year":"2022","unstructured":"Chuli\u00e1-Peris L et al (2022) Matrix metalloproteinases and their inhibitors in pulmonary fibrosis: EMMPRIN\/CD147 comes into play. Int J Mol Sci 23(13):6894. https:\/\/doi.org\/10.3390\/ijms23136894","journal-title":"Int J Mol Sci"},{"key":"1621_CR21","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.3389\/fimmu.2017.01908","volume":"8","author":"C Xia","year":"2017","unstructured":"Xia C, Braunstein Z, Toomey AC, Zhong J, Rao X (2017) S100 proteins as an important regulator of macrophage inflammation. Front Immunol 8:1908","journal-title":"Front Immunol"},{"key":"1621_CR22","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1464-9","volume":"38","author":"S Qi","year":"2019","unstructured":"Qi S et al (2019) Arf6-driven endocytic recycling of CD147 determines HCC malignant phenotypes. J Exp Clin Cancer Res 38:471. https:\/\/doi.org\/10.1186\/s13046-019-1464-9","journal-title":"J Exp Clin Cancer Res"},{"issue":"1","key":"1621_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms18010212","volume":"18","author":"B Wu","year":"2017","unstructured":"Wu B et al (2017) F-box protein FBXO22 mediates polyubiquitination and degradation of CD147 to reverse cisplatin resistance of tumor cells. Int J Mol Sci 18(1):212. https:\/\/doi.org\/10.3390\/ijms18010212","journal-title":"Int J Mol Sci"},{"key":"1621_CR24","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1002\/hep4.1911","volume":"6","author":"T Goya","year":"2022","unstructured":"Goya T et al (2022) Direct conversion of human endothelial cells into liver cancer \u2013 forming cells using nonintegrative episomal vectors. Hepatol Commun 6:1725\u20131740","journal-title":"Hepatol Commun"},{"key":"1621_CR25","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1159\/000143402","volume":"29","author":"S Sell","year":"2008","unstructured":"Sell S (2008) Alpha-fetoprotein, stem cells and cancer: how study of the production of alpha-fetoprotein during chemical hepatocarcinogenesis led to reaffirmation of the stem cell theory of cancer. Tumour Biol 29:161\u2013180","journal-title":"Tumour Biol"},{"key":"1621_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.4161\/bioa.26638","volume":"3","author":"L Maldonado-B\u00e1ez","year":"2013","unstructured":"Maldonado-B\u00e1ez L, Donaldson J (2013) Hook1, microtubules, and Rab22: mediators of selective sorting of clathrin-independent endocytic cargo proteins on endosomes. BioArchitecture 3:141\u2013146","journal-title":"BioArchitecture"},{"key":"1621_CR27","doi-asserted-by":"publisher","first-page":"4306","DOI":"10.1158\/1078-0432.CCR-05-2568","volume":"12","author":"H Huynh","year":"2006","unstructured":"Huynh H, Soo KC, Chow PKH, Panasci L, Tran E (2006) Xenografts of human hepatocellular carcinoma: a useful model for testing drugs. Clin Cancer Res 12:4306\u20134314","journal-title":"Clin Cancer Res"},{"key":"1621_CR28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1002\/hep.30481","volume":"69","author":"H Huynh","year":"2019","unstructured":"Huynh H et al (2019) Infigratinib mediates vascular normalization, impairs metastasis, and improves chemotherapy in hepatocellular carcinoma. Hepatology 69:943\u2013958","journal-title":"Hepatology"},{"key":"1621_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25031563","volume":"25","author":"WH Ng","year":"2024","unstructured":"Ng WH, Soo KC, Huynh H (2024) Vinorelbine improves the efficacy of sorafenib against hepatocellular carcinoma: a promising therapeutic approach. Int J Mol Sci 25:1563","journal-title":"Int J Mol Sci"},{"key":"1621_CR30","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1111\/cas.14534","volume":"111","author":"Y Johmura","year":"2020","unstructured":"Johmura Y, Harris AS, Ohta T, Nakanishi M (2020) FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis. Cancer Sci 111:2718\u20132725","journal-title":"Cancer Sci"},{"issue":"1","key":"1621_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1058-6","volume":"38","author":"L Zhang","year":"2019","unstructured":"Zhang L et al (2019) FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21. J Exp Clin Cancer Res 38(1):101. https:\/\/doi.org\/10.1186\/s13046-019-1058-6","journal-title":"J Exp Clin Cancer Res"},{"key":"1621_CR32","doi-asserted-by":"publisher","DOI":"10.1017\/S1462399408000744","volume":"10","author":"AM Abukhdeir","year":"2008","unstructured":"Abukhdeir AM, Park BH (2008) p21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med 10:e19. https:\/\/doi.org\/10.1017\/S1462399408000744","journal-title":"Expert Rev Mol Med"},{"key":"1621_CR33","doi-asserted-by":"publisher","unstructured":"Baba AB et al (2022) Transforming growth factor-beta (TGF-\u03b2) signaling in cancer-A betrayal within. Front Pharmacol 13. https:\/\/doi.org\/10.3389\/fphar.2022.791272","DOI":"10.3389\/fphar.2022.791272"},{"key":"1621_CR34","first-page":"6045","volume":"62","author":"M Ramachandra","year":"2002","unstructured":"Ramachandra M et al (2002) Restoration of transforming growth factor beta signaling by functional expression of Smad4 induces anoikis. Cancer Res 62:6045\u20136051","journal-title":"Cancer Res"},{"key":"1621_CR35","doi-asserted-by":"publisher","first-page":"6733","DOI":"10.1073\/pnas.95.12.6733","volume":"95","author":"A Moustakas","year":"1998","unstructured":"Moustakas A, Kardassis D (1998) Regulation of the human p21\/WAF1\/Cip1 promoter in hepatic cells by functional interactions between Sp1 and Smad family members. Proc Natl Acad Sci U S A 95:6733\u20136738","journal-title":"Proc Natl Acad Sci U S A"},{"key":"1621_CR36","doi-asserted-by":"publisher","first-page":"29244","DOI":"10.1074\/jbc.M909467199","volume":"275","author":"K Pardali","year":"2000","unstructured":"Pardali K et al (2000) Role of Smad proteins and transcription factor Sp1 in p21Waf1\/Cip1 regulation by transforming growth factor-beta. J Biol Chem 275:29244\u201329256","journal-title":"J Biol Chem"},{"key":"1621_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.dnarep.2016.04.008","volume":"42","author":"A Karimian","year":"2016","unstructured":"Karimian A, Ahmadi Y, Yousefi B (2016) Multiple functions of p21 in cell cycle, apoptosis and transcriptional regulation after DNA damage. DNA Repair (Amst) 42:63\u201371","journal-title":"DNA Repair (Amst)"},{"key":"1621_CR38","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrc2657","volume":"9","author":"T Abbas","year":"2009","unstructured":"Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9:400\u2013414","journal-title":"Nat Rev Cancer"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-026-01621-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-026-01621-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T12:07:57Z","timestamp":1787054877000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-026-01621-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,29]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["1621"],"URL":"https:\/\/doi.org\/10.1007\/s10637-026-01621-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,29]]},"assertion":[{"value":"20 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy and integrity of any part of the work are appropriately investigated and resolved.Approval for the use of patient-derived tumors: Ethics committee approval for the use of patient-derived tumors for PDX was obtained from the National Cancer Centre Singapore (NCCS) and Singapore General Hospital (approval number: #2018\/SHS\/1356) and Daiichi Sankyo (approval number: #000506). Written informed consent was obtained from all patients, and all methods related to human tissue procurement and use were performed in accordance with the relevant guidelines, regulations, and the Declaration of Helsinki.Approval for animal experiments: All animal experimental procedures were approved by the Institutional Animal Care and Use Committee (IACUC) of Daiichi Sankyo Co., Ltd. (approval numbers: 21000080, 22000382) and NCCS (IACUC approval number: #2018\/SHS\/1356). All procedures were performed in accordance with the in-house guidelines of the respective Institutional Animal Care and Use Committees and in compliance with the ARRIVE guidelines.","order":1,"name":"Ethics","label":"Ethical Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HY, SW, JT, HI, RN, MY, MH, and KF are paid employees of Daiichi Sankyo Co., Ltd. HY is a paid employee of Daiichi Sankyo Inc. (USA). This work was supported in part by research funding from Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}